plasminogen activator inhibitor

Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia.


1. any substance that interferes with a chemical reaction, growth, or other biologic activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.
ACE i's (angiotensin-converting enzyme i's) see angiotensin-converting enzyme inhibitors.
angiogenesis inhibitor a group of drugs that prevent growth of new blood vessels into a solid tumor.
aromatase i's a class of drugs that inhibit aromatase activity and thus block production of estrogens; used to treat breast cancer and endometriosis.
C1 inhibitor (C1 INH) a member of the serpin group, an inhibitor of C1, the initial component activated in the classical complement pathway. Deficiency of or defect in the protein causes hereditary angioedema.
carbonic anhydrase inhibitor an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones of uric acid.
cholinesterase inhibitor anticholinesterase.
COX-2 i's (cyclooxygenase-2 i's) a group of nonsteroidal antiinflammatory drugs that act by inhibiting cyclooxygenase-2 activity; they have fewer gastrointestinal side effects than other NSAIDs. Two members of the group are celecoxib and rofecoxib.
gastric acid pump inhibitor an agent that inhibits gastric acid secretion by blocking the action of H+,K+-ATPase at the secretory surface of gastric parietal cells; called also proton pump i.
HIV protease inhibitor any of a group of antiretroviral drugs active against the human immunodeficiency virus; they prevent protease-mediated cleavage of viral polyproteins, causing production of immature viral particles that are noninfective. Examples include indinavir sulfate, nelfinavir mesylate, ritonavir, and saquinavir.
HMG-CoA reductase i's a group of drugs that competitively inhibit the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia. Called also statins.
membrane inhibitor of reactive lysis (MIRL) protectin.
monoamine oxidase inhibitor any of a group of drugs that inhibit the action of monoamine oxidase, the enzyme that breaks down norepinephrine and serotonin, prescribed for their antidepressant action; the most widely used ones are isocarboxazid, phenelzine, and tranylcypromine. They are also used in the prevention of migraine.
α2-plasmin inhibitor α2-antiplasmin.
plasminogen activator inhibitor (PAI) any of several regulators of the fibrinolytic system that act by binding to and inhibiting free plasminogen activator. Their concentration in plasma is normally low, but is altered in some disturbances of bodily hemostasis. PAI-1 is an important fast-reacting inhibitor of t-plasminogen activator and u-plasminogen activator. Its synthesis, activity, and release are highly regulated; elevated levels of it have been described in a number of disease states. PAI-2 is a normally minor inhibitor that greatly increases in concentration during pregnancy and in certain disorders. PAI-3 is protein C inhibitor.
platelet inhibitor any of a group of agents that inhibit the clotting activity of platelets; the most common ones are aspirin and dipyridamole. See also antiplatelet therapy.
protease inhibitor
1. a substance that blocks activity of endopeptidase (protease), such as in a virus.
protein C inhibitor the primary inhibitor of activated anticoagulant protein C; it is a glycoprotein of the serpin family of proteinase inhibitors and also inhibits several other proteins involved in coagulation (thrombin, kallikrein, and coagulation factors X and XI) and urokinase. Called also plasminogen activator inhibitor 3.
proton pump inhibitor gastric acid pump i.
reverse transcriptase inhibitor a substance that blocks activity of the reverse transcriptase of a retrovirus and is used as an antiretroviral agent. Some are nucleosides or nucleoside analogues, and those that are not are therefore often called non-nucleoside reverse transcriptase inhibitors.
selective serotonin reuptake inhibitor (SSRI) any of a group of drugs that inhibit the inactivation of serotonin by blocking its absorption in the central nervous system; used as antidepressants and in the treatment of obsessive-compulsive disorder and panic disorder.
serine protease inhibitor (serine proteinase inhibitor) serpin.
topoisomerase i's a class of antineoplastic agents that interfere with the arrangement of DNA in cells.

plasminogen activator inhibitor

plasma protein active in thrombus turnover; along with tissue plasminogen activator (tPA) and lipoprotein Lp(a), was found to be increased in patients with angiographically verified coronary artery disease.

plas·min·ogen ac·tiv·a·tor in·hi·bi·tor

(PAI) (plaz-minŏ-jen akti-vā-tŏr in-hibi-tŏr)
Plasma protein active in thrombus turnover; with tissue plasminogen activator and lipoprotein, was found to increase in patients with angiographically verified coronary artery disease.


the inactive precursor of plasmin, occurring in plasma and converted to plasmin by activators present in most tissues, blood, vessel walls and body fluids; called also profibrinolysin.

plasminogen activator inhibitor
can protect the fibrin clot from premature lysis; called also PA inhibitor.
References in periodicals archive ?
Extracellular matrix of cultured bovine endothelial cells contains functionally active type 1 plasminogen activator inhibitor.
Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Tissue type plasminogen activator inhibitor, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signalling and thereby promotes MCF-7 cell growth.
Altered expression of plasminogen activator inhibitor type 1 in placenta from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.
Complete deficiency of plasminogen activator inhibitor type 1 due to frame-shift mutation.
Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer.
Concentrations of plasminogen activator inhibitor (PAI) have been reported to be increased in obese persons, particularly those with visceral obesity (56).
4] Nonstandard abbreviations: uPA, urokinase plasminogen activator; ER, estrogen receptor; uPAR, uPA receptor; and PAL plasminogen activator inhibitor.
Additionally, Corvas is pursuing novel approaches for the treatment of solid tumor cancers including the discovery and development of urokinase (uPA) inhibitors and antagonists of plasminogen activator inhibitor 1 (PAI-1), both of which have been implicated in the processes of tumor angiogenesis and metastasis.

Full browser ?